Our Science
Better cells.
Better therapies.
Better cells.
Better therapies.
Our platform is uniquely suited to solve one of the key bottlenecks in the field: the lack of good differentiation protocols to convert stem cells into target cells with mature function.
Our platform is uniquely suited to solve one of the key bottlenecks in the field: the lack of good differentiation protocols to convert stem cells into target cells with mature function.
Differentiation,
differentiated.
Differentiation,
differentiated.
Existing protocols tend to create highly immature, fetal-like cells that fail to perform key functions of adult cells. Our platform lets us efficiently discover how to make more mature cells more quickly.
Existing protocols tend to create highly immature, fetal-like cells that fail to perform key functions of adult cells. Our platform lets us efficiently discover how to make more mature cells more quickly.
Existing protocols tend to create highly immature, fetal-like cells that fail to perform key functions of adult cells. Our platform lets us efficiently discover how to make more mature cells more quickly.
A new frontier in liver cell maturation
A new frontier in liver cell maturation
For stem cell differentiation into liver cells, we have made a breakthrough improvement in maturation compared to state of the art baseline, as measured by gold-standard metabolic assays of clinically-relevant liver functions.
For stem cell differentiation into liver cells, we have made a breakthrough improvement in maturation compared to state of the art baseline, as measured by gold-standard metabolic assays of clinically-relevant liver functions.
Building a pipeline of therapeutic cell types
Building a pipeline of therapeutic cell types
We are applying the same approach to unlock differentiation protocols for new cell types across indications with high unmet need.
We are applying the same approach to unlock differentiation protocols for new cell types across indications with high unmet need.
We are applying the same approach to unlock differentiation protocols for new cell types across indications with high unmet need.
Work with us
Work with us
We’re partnering with leading teams to build the next generation of cell therapies. Interested in our pipeline?
We’re partnering with leading teams to build the next generation of cell therapies. Interested in our pipeline?
© 2025 Stately Bio Inc. All rights reserved.